AbbVie Acquires Apogee for $10.9B, Insilico AI Secures $2.5B Deal with SK Biopharmaceuticals, and Innovent’s IBI3003 Shows Breakthrough Efficacy in Myeloma

Jul 02, 2026 16:30 CST Updated 16:30

ANTENGENE CORPORATION

Innovative Oncology Drug Developer

K2 Therapeutics

Innovative Drug Developer

LyncBio Therapeutics

ADC Drug Developer

Artivila

Innovative Drug Developer

ZYBio

Probiotics and Live Biotherapeutics Developer

Haisco

New Drug Research and Development, Production, and Sales

CStone Pharmaceuticals

Innovative Oncology Immunotherapy and Precision Medicine Drug Developer

Leads Biolabs

Innovative Therapy Developer

Global Biopharmaceutical Industry Trends

In terms of capital markets

Intensive Closure of Industry Collaborations, Financing, and M&A Deals: Antengene Corporation signed an exclusive overseas license agreement with K2 Therapeutics for its CDH6×CD3 bispecific antibody, along with an option for another bispecific candidate; both projects carry maximum milestone payments of $960.5 million, excluding Greater China rights. Xihu Biology completed over RMB 100 million in financing to advance the clinical industrialization of its red blood cell-based drug pipeline for oncology and autoimmune indications. AbbVie acquired Apogee for $10.9 billion in cash to strengthen its autoimmune pipeline, marking its second cell therapy platform investment within the year. ZYBio filed for a main board listing on the Hong Kong Stock Exchange; its live biotherapeutic product SK08 has entered Phase III trials, maintaining a leading pipeline progress despite continued losses in 2025. Fanli Bio out-licensed two TL1A antibodies, with total overseas deal value reaching $985 million, while simultaneously facilitating a $165 million Series A financing round for its partner. Insilico Medicine partnered with SK Biopharmaceuticals on an AI-driven new drug collaboration valued at up to $2.5 billion, focusing on neuroimmune diseases. Haisco licensed two small-molecule assets to Nuvectis, with total overseas transaction value amounting to $1.461 billion. LyncBio Therapeutics closed nearly RMB 100 million in Pre-A+ financing, advancing its autoimmune ADC pipeline into clinical stages. Allist Pharmaceuticals expanded its global R&D collaboration with Eli Lilly, with potential total transaction value reaching $1.9 billion. Sangamo spun off its gene platform and rare disease pipeline, selling them to Eli Lilly and Astellas respectively, while simultaneously initiating bankruptcy restructuring. Lingtaike Biology consecutively completed Series A and A+ financing rounds, deepening its focus on lncRNA nucleic acid drug delivery technology. Artivila secured nearly RMB 100 million in Series A financing to bolster its AI-driven drug discovery efforts. CStone Pharmaceuticals granted Arrotex commercialization rights for sugemalimab in Australia and New Zealand. Oblenio Bio, the joint venture of Leads Biolabs, completed a $62 million Series B financing round to advance its trispecific T-cell engager (TCE) into clinical development.

Clinical Progress

Positive News Frequently Emerges in Oncology, Dermatology, Neurology, and Rare Diseases: Inxite’s IBI3003 Trispecific Antibody for Relapsed Multiple Myeloma Discloses High Response Rates in Phase I/II Clinical Trials, with an ORR of 83.3% in the ≥120 μg/kg Dose Group; First Patient Dosed in Pivotal Phase III Trial; Chenguang’s CG2001 Meets Primary Endpoint in Phase II Trial for Androgenetic Alopecia, Showing Significantly Greater Improvement in Hair Density Compared to Placebo (Chenguang Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)）; Otsuka’s centanafadine demonstrates dual-endpoint benefits in Phase IIIb trials for ADHD comorbid with anxiety, with synchronous improvements in mood and behavioral scores; Capricor’s deramiocel Phase III 5-year long-term data confirm stabilization of cardiopulmonary function in Duchenne muscular dystrophy; Johnson & Johnson registers a large-scale Phase III trial of a triple-antibody combination including a CD38 antibody as first-line therapy for myeloma, planning to enroll 1,000 treatment-naïve patients; Kelun-Biotech’s clinical trial application for SKB500 combination therapy in esophageal squamous cell carcinoma receives implicit approval from the NMPA.

Industry Strategic Adjustments

Accelerated Capitalization in Pharmaceutical Enterprises and Continuous Upgrading of R&D Models: Multiple companies are increasing investments in core platforms such as bispecific/trispecific T-cell engagers (TCEs), antibody-drug conjugates (ADCs), lncRNA therapeutics, gene editing, and AI-driven drug discovery. Domestic pharmaceutical companies are batch-advancing overseas licensing of their pipelines and commercial collaborations in foreign regions, while multinational pharmaceutical firms are securing domestic innovative assets through large-scale acquisitions and early-stage R&D partnerships. AI-driven new drug discovery, multispecific antibodies, and gene delivery technologies have become the core directions for industry upgrading, with platform licensing, major M&A transactions, primary market financing, and IPO filings forming a normalized industrial cycle.

Global Biopharmaceutical Industry

Major Events

Global Innovative Drugs

Key Clinical Advances/Outcomes

Global Innovative Drugs

Major Investment, Financing, and Transaction Events

Weekly Summary

From June 22 to June 28, 2026, biopharmaceutical investment, financing, and collaborative transactions remained active. Antengene Corporation (6996.HK) signed an exclusive overseas license agreement with K2 Therapeutics for a CDH6 x CD3 bispecific T-cell engager (TCE) and granted an option for another bispecific antibody; the combined maximum milestone payments for the two deals totaled nearly $2 billion, with Antengene also retaining a minority equity stake in the collaborating entity. Westlake Biopharma completed over RMB 100 million in financing to advance the clinical development and industrialization of its global-first red blood cell-based drug pipeline for oncology and autoimmune diseases. AbbVie acquired Apogee for $10.9 billion to strengthen its autoimmune pipeline, complementing its earlier $2.1 billion acquisition at the beginning of the year to enhance in vivo cell delivery technologies. ZYBio submitted an application for listing on the Main Board of the Hong Kong Stock Exchange; its core live biotherapeutic product, SK08, has entered Phase III clinical trials and is poised to become the first biologic for irritable bowel syndrome (IBS). Fanli Biologics outlicensed the overseas rights to two TL1A-series antibodies to Bionyra, with the total transaction value equivalent to RMB 6.6 billion; concurrently, the partner completed a $165 million Series A financing round. Insilico Medicine and SK Biopharmaceuticals reached a collaboration on AI-driven neuroimmunology novel drugs worth over $2.5 billion, marking SK’s largest partnership in the Asia-Pacific region. Haisco finalized overseas licensing deals for two small-molecule new drugs valued at $1.461 billion. LyncBio Therapeutics completed a Pre-A+ financing round of nearly RMB 100 million, advancing its global-first autoimmune antibody-drug conjugate (ADC) into Phase I clinical trials. Abivax (Note: Corrected from context, likely refers to Abbisko/Abisko based on ticker 02256.HK which is Abbisko) — *Correction*: Abbisko Pharmaceuticals (02256.HK) once again partnered with Eli Lilly, with a potential total value of $1.9 billion. Sangamo sold its gene delivery and rare disease pipelines to Eli Lilly and Astellas, respectively, and initiated bankruptcy restructuring. Lingtaike Biopharma consecutively completed Series A and A+ financing rounds to tackle the challenge of extrahepatic delivery for lncRNA nucleic acid therapeutics. Artivila secured nearly RMB 100 million in Series A financing to bolster AI-driven new drug R&D. CStone Pharmaceuticals (2616.HK) granted Arrotex exclusive commercialization rights for sugemalimab in Australia and New Zealand. Oblenio Bio, the joint venture of Leads Biolabs, completed a $62 million Series B financing round to advance the clinical development of its trispecific TCE.

Investment and Financing

Xihu Biology — Over RMB 100 Million in Financing

Update: Recently, Westlake Biopharmaceutical Technology Co., Ltd. (Westlake Bio) announced the completion of a new round of financing exceeding RMB 100 million. This round was co-led by Beijing Shijingshan District Modern Innovation Industry Development Fund Co., Ltd. (Shijingshan Modern Innovation Industry Fund) and Ruili Synthetic Biology Fund, with participation from renowned industrial investors. Existing shareholders, including Yifeng Capital, Huafang Capital, and Sequoia China, continued to increase their investments.

Significance: The proceeds from this round of financing will be primarily used to advance the development of the company’s pipeline of red blood cell-based therapeutics in areas such as oncology and autoimmune diseases, accelerate clinical validation and regulatory filings for core products, and further strengthen capabilities in R&D, manufacturing, and industrialization.

ZYBio — Applying for Hong Kong Stock Exchange Listing

Update: On June 18, Guangzhou Zhiyi Biotechnology Co., Ltd. submitted an application for a main board listing to the Hong Kong Stock Exchange, with SDIC Securities International and Industrial Securities International serving as joint sponsors. As a clinical-stage biopharmaceutical company, it focuses on the research and development of live biotherapeutic products (LBPs). Its core product, SK08, targets indications such as irritable bowel syndrome, while its key product, SK10, is used for the prevention and treatment of chemotherapy-induced diarrhea. The company also has four preclinical candidate drugs in its pipeline.

Significance: ZYBio has established an LBP R&D pipeline covering gastrointestinal diseases and tumor-related complications. SK08 has initiated Phase III clinical trials (launched in March 2024, with primary efficacy endpoint assessment expected to be completed in Q4 2027), and SK10 is planned to enter Phase II clinical trials in Q1 2028. SK08 is the first Bacteroides fragilis LBP globally to enter clinical development; if approved, it is poised to become the first marketed biologic drug for irritable bowel syndrome.

Bionyra Pharma — $165 Million Series A Financing

Update: On June 22, Bionyra Pharma announced the completion of a $165 million Series A financing round. The round was co-led by Jeito Capital and Sofinnova Partners, with participation from Arkin Capital, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures.

Significance: This round of financing was completed concurrently with the licensing agreement with Fanli Bio, and the proceeds will be used to advance the global development and commercialization of two investigational antibody drugs licensed from Fanli Bio: the anti-TL1A monoclonal antibody TL-001 and the anti-TL1A/IL-23p19 bispecific antibody TL-003.

LyncBio Therapeutics — Nearly RMB 100 Million Pre-A+ Financing Round

LyncBio Therapeutics Announces Completion of Nearly RMB 100 Million Pre-A+ Financing RoundRecently, Lyncbio Therapeutics Co., Ltd. (LyncBio Therapeutics) announced the completion of its Pre-A+ financing round, raising nearly RMB 100 million. This round took place just five months after the previous financing. The round was led by Boyuan Capital, with existing shareholder Xingze Capital continuing to increase its investment. Previously, the company had successfully completed a seed financing round of tens of millions of RMB and a Pre-A financing round of nearly RMB 100 million.

Significance: The proceeds from this round of financing will be used to accelerate the global multi-center clinical trials of the company’s core pipeline, while also expanding the innovative pipeline across multiple therapeutic areas based on the company’s proprietary technology platforms, Zent-iDC™ and Gemini-TDC™, thereby optimizing the strategic layout of its early-stage pipeline.

Lingtaike Biotech — Series A and A+ Financing Rounds

Updates: Recently, Chengdu Lingtaike Biotechnology Co., Ltd. (lncTAC) announced the consecutive completion of its Series A and Series A+ financing rounds. The Series A round was led by DragonRock Investment, while the Series A+ round was led by Panlin Capital, with participation from Huafang Capital, Imeik, and Sunshine Ronghui Capital. Existing shareholder Legend Capital continued to increase its investment. Founded in 2021, the company is the first biotechnology enterprise in China dedicated to the research and development of core technologies for modular drugs based on long non-coding RNA (lncRNA).

Significance: The financing will accelerate the critical process of translating lncRNA from validation to commercialization, aiming to overcome the bottleneck of extrahepatic delivery of nucleic acid drugs and develop next-generation nucleic acid therapeutics for major disease areas such as transdermal applications, oncology, and the central nervous system (CNS).

Artivila — Nearly 100 Million Yuan in Series A Financing

News: Artivila recently successfully completed its Series A financing round, raising nearly RMB 100 million. The round was led by Sinopharm Capital, with participation from Junyi Investment and others. Kaicheng Capital served as the exclusive financial advisor for subsequent financing rounds. The company focuses on improving patients' lives through an AI-driven drug discovery engine and is dedicated to developing therapies for neurodegenerative diseases, autoimmune disorders, and oncology.

Significance: The proceeds from this financing round will be primarily used to strengthen the R&D platform and product pipeline, support corporate operations and international business development, with a particular focus on the clinical development of core pipeline assets.

Oblenio Bio — $62 Million Series B Financing

Update: On June 25, Oblenio Bio, the joint venture between Leads Biolabs and Aditum Bio, successfully closed an oversubscribed $62 million Series B financing round. The round was led by Pfizer Ventures, with participation from Deep Track Capital, GV, and Aditum Bio, a founding investor in Oblenio.

Significance: This milestone will significantly advance the clinical development of LBL-051 (a tri-specific T-cell engager licensed from Leads Biolabs).

Tengdi Biologics — $7.5 Million Seed+ Financing Round

Update: 20n Bio, a biotechnology company focused on the discovery of novel cyclic peptide drugs, recently announced the completion of a $7.5 million Seed+ financing round. The round was led by a leading industrial strategic investor and participated by a London-based life sciences venture capital fund.

Significance: The proceeds from this round of financing will be primarily used to further strengthen Tengdi Biologics' high-throughput cyclic peptide discovery platform, promote the comprehensive integration of AI technology into the cyclic peptide discovery and optimization processes, and advance the development of the company's proprietary innovative drug pipeline.

Transaction Authorization

ANTENGENE CORPORATION × K2 Therapeutics — Exclusive License for ATG-106 + Option for Bispecific TCE

Update: On June 22, Antengene Corporation (6996.HK) announced that it had entered into an exclusive licensing agreement with K2 Therapeutics, a company founded by MPM BioImpact, for ATG-106, and granted it an option to an undisclosed bispecific T-cell engager (TCE). ATG-106 is a CDH6 x CD3 bispecific T-cell engager (TCE) in preclinical development for the treatment of solid tumors. The rights related to K2 Therapeutics cover the global market, excluding Greater China.

Amount: Under the license agreement, Antengene Corporation is entitled to an upfront payment and near-term consideration of approximately USD 20 million (including cash and a minority equity interest in a newly established asset company of K2 Therapeutics), and is eligible to receive up to USD 960.5 million in development, regulatory, and commercial milestone payments, as well as tiered royalties. Upon exercise of the option, Antengene Corporation may also receive an upfront payment and near-term consideration of approximately USD 20 million, and milestone payments of up to USD 960.5 million.

AbbVie × Apogee Therapeutics — Acquisition

Update: According to the Financial Times, AbbVie has reached an agreement to acquire Apogee Therapeutics for $10.9 billion in cash. This deal underscores the growing interest in innovative therapies within the biotechnology sector, particularly in the fields of immunology and autoimmune disease treatment.

Significance: The proposed acquisition aligns with AbbVie’s recent strategic initiatives to strengthen its immunology portfolio. Earlier this year, AbbVie announced the $2.1 billion acquisition of Capstan Therapeutics, gaining access to its proprietary tLNP platform technology and key asset CPTX2309 (the first potential in vivo anti-CD19 CAR-T therapeutic candidate for B cell-mediated autoimmune diseases).

Fanli Biotech × Bionyra Pharma — Exclusive Licensing of Two Antibody Drugs

Update: On June 22, Fanli Biologics announced the signing of an exclusive licensing agreement with Bionyra Pharma, a clinical-stage biopharmaceutical company, covering two investigational antibody drugs: an anti-TL1A monoclonal antibody (code name TL-001) and an anti-TL1A/IL-23p19 bispecific antibody (code name TL-003). Bionyra has obtained exclusive global rights, excluding the Greater China region, to research, develop, manufacture, and commercialize the aforementioned two drugs.

Amount: Fanli Biologics is entitled to receive total payments of up to $985 million (approximately RMB 6.6 billion), including an upfront payment and milestone payments based on development, regulatory, and commercialization progress, as well as tiered royalties based on future net sales of the products. As of the press date, Fanli Biologics has received tens of millions of US dollars in upfront and milestone payments and will hold a certain percentage of equity in Bionyra following its Series A financing round.

Insilico Medicine × SK Biopharmaceuticals — AI-Driven Drug Discovery Collaboration

News: Recently, Insilico Medicine and SK Biopharmaceuticals announced an AI-driven drug development collaboration focused on innovative drug discovery in the field of neuroimmunological diseases.

Deal Value: The total potential value of this collaboration exceeds $2.5 billion, marking the largest transaction Insilico Medicine has ever closed with a partner in the Asia-Pacific region. Insilico Medicine will receive an upfront payment and near-term milestone payments totaling up to $18 million, along with subsequent payments tied to development, regulatory, and commercial milestones, as well as single-digit percentage royalties on net sales post-commercialization.

Haisco × Nuvectis Pharma — Overseas Licensing of Two Novel Small-Molecule Drugs

Update: On June 22, Nuvectis Pharma (NASDAQ: NVCT) announced that it had acquired two potential best-in-class clinical-stage compounds through an exclusive out-of-China licensing agreement with Haisco Pharmaceutical. Haisco Pharmaceutical, which has approximately 50 marketed products and 70 research projects, has recently gained recognition for the successful execution of licensing agreements with Eli Lilly and AbbVie (both in Q2 2026) and for the successful Phase 3 clinical trial of its TYK2 inhibitor envudeucitinib in plaque psoriasis (Q1 2026).

Amount: US$1.461 billion.

Abbisko Therapeutics × Eli Lilly — Deepening Collaboration on New Drug Development

Update: On June 24, Abbisko Therapeutics (02256.HK) announced the signing of a strategic R&D collaboration and licensing agreement with Eli Lilly and Company. The two parties will collaborate on innovative drug development around multiple disease targets, jointly advancing new drug projects with global potential. Leveraging its early-stage drug discovery platform and innovative R&D system, Abbisko Therapeutics will conduct drug discovery and early-stage development for new drug projects targeting disease areas selected by Eli Lilly.

Amount: Abbisko Therapeutics will receive an upfront payment and is eligible for further payments upon achieving subsequent development, regulatory, and commercialization milestones, with a potential total value of up to $1.9 billion. It will also be entitled to tiered royalties based on future net sales of the products. In 2022, Abbisko Therapeutics and Eli Lilly previously signed a global collaboration and exclusive license agreement.

Sangamo × Eli Lilly/Astellas — Asset Sale Agreement

Updates: On June 23, Sangamo Therapeutics announced the execution of two separate asset purchase agreements: with Eli Lilly for Sangamo’s capsid delivery platform, zinc finger platform, modular integrase (MINT) platform, and prion disease pipeline candidate ST-506; and with Astellas for the Fabry disease pipeline candidate isaralgagene civaparvovec (ST-920). Concurrently with the execution of these agreements, Sangamo has initiated voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware to facilitate a court-supervised restructuring, which is expected to include an auction of substantially all of Sangamo’s assets.

CStone Pharmaceuticals × Arrotex — Exclusive Commercialization Partnership for Sugemalimab

Update: On June 25, CStone Pharmaceuticals (2616.HK) announced an exclusive commercialization partnership with Arrotex Pharmaceuticals, the core pharmaceutical commercialization platform under DBG Health, a leading integrated healthcare group in Australia, for sugemalimab in Australia and New Zealand. Arrotex will obtain exclusive commercialization rights for sugemalimab in Australia and New Zealand, covering all approved and future potential indications (including Stage III and IV non-small cell lung cancer [NSCLC], gastric cancer, esophageal squamous cell carcinoma, and extranodal NK/T-cell lymphoma). Arrotex will be responsible for regulatory submissions and commercial promotion in the licensed territories.

Amount: CStone Pharmaceuticals will receive an upfront payment and subsequent additional regulatory and sales milestone payments from Arrotex, and will be responsible for supplying sugemalimab to Arrotex, receiving revenue sharing in the licensed territory.

Leads Biolabs × Aditum Bio/Oblenio Bio — Tri-specific TCE Licensing (NewCo Model)

Update: On June 25, Leads Biolabs announced that its joint venture with Aditum Bio, Oblenio Bio, successfully completed an oversubscribed $62 million Series B financing round, led by Pfizer Ventures, which will significantly advance the clinical development of LBL-051. LBL-051 is a tri-specific T-cell engager (TCE) licensed from Leads Biolabs.

Global Regulatory Dynamics for Innovative Drugs

(Approved for Marketing/IND/Special Review)

China NMPA Regulatory Updates (Market Authorization Acceptance and Policies)

Shuruijioluncai Injection (Brand Name: Kailimei)

Company: CARsgen Therapeutics (Shanghai CARsgen Pharmaceutical)

Date: June 22, 2026

Details: Approved for marketing by the NMPA, this Class 1 innovative drug is the world’s first CAR-T therapy for solid tumors. It is indicated for the treatment of advanced gastric/gastroesophageal junction adenocarcinoma that is CLDN18.2-positive and HER2-negative, in patients who have failed at least two prior lines of therapy, thereby filling the commercialization gap for CAR-T therapies in solid tumors.

Lunkang Yilongtuo Monoclonal Antibody (Trade Name: Yizekang, BL-B01D1 for Injection)

Enterprise: Sichuan Baili Tianheng Pharmaceutical

Date: June 22, 2026

Details: Approved by the NMPA for marketing, this is the world’s first approved EGFR×HER3 bispecific antibody-drug conjugate (ADC), indicated for recurrent/metastatic nasopharyngeal carcinoma that has progressed after prior treatment with PD-1/PD-L1 monoclonal antibodies and at least two lines of platinum-based chemotherapy, providing a novel targeted therapeutic option for advanced nasopharyngeal carcinoma.

Yilunsiqun

Company: Eli Lilly

Date: June 22, 2026

Details: Approved for marketing by the NMPA, this is China’s first oral SERD inhibitor. It is used as monotherapy or in combination with abemaciclib for adult patients with ER+/HER2-, ESR1-mutated locally advanced or metastatic breast cancer, addressing the clinical challenge of endocrine therapy resistance.

Niraparib and Abiraterone Tablets (Brand Name: Zebeike)

Company: Johnson & Johnson (Janssen)

Date: June 22, 2026

Details: The NMPA has approved a new indication for use in combination with prednisone/prednisolone in adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) harboring BRCA2 mutations, expanding the options for precision combination therapy in prostate cancer.

Pelargonium Spray (Brand Name: Puyike)

Company: Playmed (Jiangsu) Co., Ltd.

Date: June 22, 2026

Details: A Class 1 innovative drug has been approved by the NMPA for market launch. This topical antimicrobial peptide medication is indicated for secondary wound infections in first-degree and superficial second-degree burns and scalds caused by pathogens such as Staphylococcus epidermidis and Acinetobacter baumannii, filling a gap in the new drug pipeline for antimicrobial peptides in wound care.

Silevemab

Company: Chongqing Zhixiang Jintai

Date: June 22, 2026

Details: Approved for marketing by the NMPA, this innovative bispecific antibody drug is indicated for autoimmune disease-related conditions, enriching the commercial pipeline of bispecific antibodies in China.

Adebrelimab

Company: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Date: June 25, 2026

Details: The NMPA has approved a new indication for use in combination with platinum-based chemotherapy as neoadjuvant therapy for resectable Stage II, IIIA, and IIIB non-small cell lung cancer (NSCLC), followed by postoperative monotherapy as adjuvant treatment, thereby completing the perioperative immunotherapy portfolio for lung cancer.

Pembrolizumab (brand name: Keytruda)

Company: MSD

Date: June 25, 2026

Details: The NMPA approved a new indication, in combination with paclitaxel (± bevacizumab), for platinum-resistant recurrent ovarian cancer, expanding the application of PD-1 inhibitors in the treatment of gynecologic tumors.

Anviacridine Succinate Tablets

Enterprise: Tonghua Jinma Pharmaceutical

Date: June 25, 2026 Details: Approved by the NMPA for market launch, indicated for the treatment of mild to moderate Alzheimer's disease (AD), providing a new oral therapeutic option for dementia patients in China.

U.S. FDA Regulatory Updates (Special Designations and Status)

Sacituzumab govitecan (Trodelvy, sacituzumab govitecan)

Company: Gilead Sciences (Gilead)

Date: Late June 2026

Details: The FDA has approved two new first-line indications for triple-negative breast cancer (TNBC), involving the combination of immune checkpoint inhibitors for the first-line treatment of unresectable locally advanced or metastatic TNBC, further solidifying the role of antibody-drug conjugates (ADCs) in the first-line treatment of breast cancer.

Palbociclib (Ibrance)

Company: Pfizer

Date: Late June 2026

Details: The FDA has approved a new indication for maintenance therapy following induction chemotherapy in HR+/HER2+ metastatic breast cancer, extending long-term survival benefits for patients with advanced breast cancer.

Elecoglipron（AZD5004）

Company: AstraZeneca

Date: June 23, 2026

Details: An oral small-molecule GLP-1 receptor agonist has initiated four pivotal Phase III clinical trials for type 2 diabetes with inadequate glycemic control. Administered once daily without the need for sustained-release formulations, it aims to establish a differentiated oral pipeline for glucose-lowering and weight management, benchmarked against semaglutide.